BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc. (BBOT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
bbot · stock forecast · 3 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$24.00
Consensus
$22.00
+180.8% upside
Low
$18.00
Median: $23 · Last Close: $7.83
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$22.00
180.8% upside
High Target
$24
206.3%
Low Target
$18
129.7%
Current Price
$7.83
as of today
Based on analyst price targets, the BBOT stock price prediction for the next 12 months ranges from $18 to $24. The consensus BBOT price forecast of $22.00 implies 180.8% upside from the current price of $7.83.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $7.59 | ↓ 3.07% |
1-day model range: $7.55–$7.64. Peak: $7.64 (-3.07%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $7 | -16.1% |
| 2028 | $6 | -23.5% |
| 2029 | $6 | -27.2% |
| 2030 | $6 | -29.1% |
| 2031 | — | -30.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · BBOT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-11 | Wedbush | Maintains | Outperform→Outperform |
| 2025-11-25 | Wedbush | Maintains | Outperform→Outperform |
| 2025-11-13 | Oppenheimer | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on BridgeBio Oncology Therapeutics Inc. (BBOT) stock. Of the recent 4 rating actions, 0 were upgrades and 0 were downgrades. 3 analysts currently cover BBOT.
Analyst Recommendation Trends
BBOT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$29M
EPS This Year
$-2.24
EPS Next Year
$-2.14
↓ 4.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast BBOT EPS of $-2.24 for the current fiscal year, based on estimates from 6 analysts. The BBOT revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BBOT stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BBOT price target is $22.00 (+180.8% upside), with an analyst consensus of Buy.
The BBOT short-term stock prediction for tomorrow is $7.59 (-3.07%). The BBOT stock price prediction for 2027 estimates an average of $7. The BBOT stock prediction for 2030 projects a range of $5–$6.
BridgeBio Oncology Therapeutics Inc. trades on NASDAQ under the ticker BBOT. The BBOT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
BBOT forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month BBOT price target is $22.00, with a high forecast of $24.00 and a low of $18.00. The median price target is shown in the chart above when available. This implies +180.8% potential upside from the current price of $7.83.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.